To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
At Karmanos, we believe in care beyond medicine and stand united with the community in the fight against cancer. Our monthly newsletter, ‘Caring. Healing. Informing.’ is an essential part of this commitment. Patients, families, caregivers, friends, and community members in the 46 counties we serve are connected by this newsletter – a beacon of hope and knowledge. From new, industry-leading cancer treatments to inspiring stories of resilience from our patients, including groundbreaking updates in research and care and information about special events, you’ll feel part of Team Karmanos. Stand with us and sign up to receive ‘Caring. Healing. Informing.’ and be part of our story.
The Barbara Ann Karmanos Cancer Institute’s Office of Community Outreach and Engagement (COE) has been named a 2025 Hometown Health Hero by the Mi...
The Barbara Ann Karmanos Cancer Institute has been named one of 168 medical centers in the country to which Optum recommends its payers refer thei...
Human papillomavirus (HPV) is common and widespread virus, and about 85% of people will get an HPV infection in their lives. According to the Cent...